ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficiency of Physiotherapeutic Care in Parkinson's Disease

This study has been completed.

Sponsors and Collaborators: Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by: Radboud University
ClinicalTrials.gov Identifier: NCT00330694
  Purpose

In the course of their disease, most patients with Parkinson's Disease (PD) face mounting mobility deficits, including difficulties with walking, balance, posture and transfers. This frequently leads to (fear of) falls, injuries, loss of independence, and inactivity which causes social isolation and increases the risk of osteoporosis or cardiovascular disease. These mobility deficits are difficult to treat with drugs and neurosurgery. However, physiotherapy is deemed effective in improving mobility deficits in PD. Physiotherapy is widely prescribed for this purpose in the Netherlands. Yet, the efficiency of current "usual care" physiotherapy can be questioned, for two reasons. First, the referral process seems inadequate because patients are mainly referred by neurologists who often lack insight into the (im-)possibilities of physiotherapy for PD. Consequently, patients with a real need for physiotherapy are not always referred (undertreatment), whereas others without a real need are (overtreatment). Furthermore, most therapists treating PD patients are not specifically trained in treating these patients. This is not surprising because average therapists rarely treat more than two patients per year in their practice. Therefore, patients who are being referred probably receive suboptimal treatment.

The objective of this study is to evaluate whether the efficiency of physiotherapeutic care for patients with Parkinson's disease can be improved, at a reduced cost, by targeting two key elements of the current care system: a) inadequate referral by neurologists; b) suboptimal treatment by physiotherapists. We expect that optimal referral combined with expert treatment will increase the efficiency, as reflected by increased health benefits for patients at equal or reduced costs'.


Condition Intervention Phase
Parkinson's Disease
Other: ParkNet
Other: Usual Care
Phase III

Genetics Home Reference related topics:   familial paroxysmal nonkinesigenic dyskinesia    Parkinson disease   

MedlinePlus related topics:   Caregivers    Parkinson's Disease   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title:   Efficiency of Physiotherapeutic Care in Parkinson's Disease

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Modified MACTAR scale [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Parkinson Activity Scale (secondary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Costs [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Proportion of correct referrals (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Quality of physiotherapy(tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Incidence of Falls (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • ALDS (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • SF-36 (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • EQ-5D (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Satisfaction of patients and professionals (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Self Assessment Disability Scale (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Freezing of Gait Questionnaire {tertiary} [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 6 meter walk test {tertiary} [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 4x3 meter walk test (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Single leg stance (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Posture and Gait score (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Timed Up and Go (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Falls Efficacy Scale {tertiary} [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • 9-hole pegboard test {tertiary} [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Health Anxiety and Depression Scale (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Physical activities assessed with the LAPAQ questionnaire (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Caregiver burden assessed with the Care Giver Strain Index (tertiary) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • PDQ-39 (Mobility Scale) [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment:   708
Study Start Date:   May 2006
Study Completion Date:   July 2007
Primary Completion Date:   July 2007 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
I: Experimental
Implementation of ParkNet within 8 regions
Other: ParkNet
Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
II
Usual Care in 8 regions
Other: Usual Care
No altered organisation of physiotherapy care in Parkinson's Disease

Detailed Description:

Design In a Cluster Randomised Trial, 16 clusters will be randomly allocated to either network care (8 clusters with an altered organisation of physiotherapeutic care) or usual care (8 clusters with unchanged organisation of physiotherapeutic care). Clusters are formed by all PD patients living in the communities connected to participating regional hospitals in the 16 clusters.

The health care intervention in the experimental group has two elements: (a) an improved quality of referrals by neurologists; and (b) an improved quality of interventions by physiotherapists. Brief description Network Care: In each of the Network Care clusters, 5 to 7 motivated therapists are selected to enroll in a regional ParkNet and consequently trained. Training is focused at correct use of the evidence-based guidelines for physiotherapy in PD (Keus et al, 2006). This training consists of a 5-day competence-oriented course, web-based continues education supported by seminars, and use of a PD specific electronic patient record. Neurologists are informed about indications for referral to physiotherapy. Improved communication between neurologist and ParkNet therapists is initiated and supported.

Following implementation of the health care change, PD patients attending the neurological outpatient clinics of the individual hospitals within the clusters will be asked to participate. During a period of 6 months, PD patients will enrol in the study. Enrollees will be followed for 6 months to measure the use and quality of physiotherapy, patient health benefit and satisfaction, and costs.

  Eligibility
Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients with idiopathic PD, diagnosed according to the Brain Bank criteria of the UK Parkinson's Disease Society
  • Living independently in the community
  • Able to complete the trial questionnaires.

Exclusion Criteria:

  • Atypical parkinsonian syndromes
  • Hoehn & Yahr stage 5
  • Severe cognitive impairment
  • Presence of major psychiatric disorders
  • Severe co-morbidity (e.g. cancer) that interferes with daily functioning.
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00330694

Locations
Netherlands
Jeroen Bosch Hospital    
      's Hertogenbosch, Netherlands
Reinier de Graaf Groep    
      Delft, Netherlands
Slingeland Ziekenhuis    
      Doetinchem, Netherlands
Catharina Ziekenhuis    
      Eindhoven, Netherlands
Maxima Medisch Centrum    
      Eindhoven, Netherlands
Ziekenhuis Hilversum    
      Hilversum, Netherlands
Ziekenhuis Gooi Noord    
      Blaricum, Netherlands
Medisch Centrum Alkmaar    
      Alkmaar, Netherlands
Kennemer Gasthuis    
      Haarlem, Netherlands
Gelre Ziekenhuizen    
      Zutphen, Netherlands
Ziekenhuis Bernhoven    
      Oss, Netherlands
Westfries Gasthuis    
      Hoorn, Netherlands
't Lange land ziekenhuis    
      Zoetermeer, Netherlands
Medisch Centrum Haaglanden, Westeinde    
      Den Haag, Netherlands
Viecurie Medisch Centrum    
      Venlo, Netherlands
Ziekenhuis Gelderse Vallei    
      Ede, Netherlands
Gelre Ziekenhuis    
      Apeldoorn, Netherlands
Groene Hart Ziekenhuis    
      Gouda, Netherlands

Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development

Investigators
Principal Investigator:     Marten Munneke, PhD     UMC st Radboud    
Principal Investigator:     Bastiaan R Bloem, MD, PhD     UMC st Radboud    
  More Information


Responsible Party:   UMC St Radboud, Neurology ( Dr M Munneke )
Study ID Numbers:   945-04-357
First Received:   May 24, 2006
Last Updated:   September 1, 2008
ClinicalTrials.gov Identifier:   NCT00330694
Health Authority:   Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Radboud University:
Physical Therapy  
Organisation of care  

Study placed in the following topic categories:
Ganglion Cysts
Movement Disorders
Parkinson Disease
Basal Ganglia Diseases
Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

Additional relevant MeSH terms:
Nervous System Diseases

ClinicalTrials.gov processed this record on October 03, 2008




Links to all studies - primarily for crawlers